The Omicron Narrative
The new variant is upon us and the narrative has been set, repeating many of the familiar reactions we have ...
Where to Receive COVID-19 Treatment
As much as we discuss the drugs used to treat COVID-19, few know where to receive them should they develop ...
Is Europe a Leading Indicator for COVID-19?
As we enter the second pandemic winter, we look for signs indicating whether COVID-19 will worsen. Europe has typically served ...
Exceptions to Common Sense Law
The courts recently ruled vaccine mandates as unconstitutional and against public interests. But by emphasizing economic interests over public health ...
Of Thoughts and Language
The push for healthcare equity has profoundly changed the way we view healthcare, including how we speak in medical settings. ...
Financial Toxicity
Mr. S did everything he could to beat his cancer. In the end, it was not the cancer but the ...
The Hospital’s Eyes
Paul the hospital janitor may appear lowly in the eyes of those who pass him by. However, he keenly observes ...
An Evening’s Kiss
Sarah and Evan are on a date and decide to go for a walk. But to find true love, they ...
Irony of Measuring Physician Burnout
Physician burnout is finally receiving the recognition it deserves. And in our world of quantitative medicine, we seek to measure ...
Peer Reviewed by Social Media
Clinical research and social media have a bizarre relationship, a complex interdependence that we have yet to fully understand. The ...
A Matter of Good Faith
The Supreme Court has agreed to clarify the question of good faith as it pertains to physician prescribing behavior. In ...
Pandemic Policy Reversals were Predicted
The pandemic has been characterized by poorly conceived policies and their inevitable reversals - with subsequent public outrage. However, these ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more